SMS Pharmaceuticals rose 1.74% to Rs 35 after it received an establishment inspection report (EIR) from US drug regulator for its Andhra Pradesh-based API facility.
The drug maker in an exchange filing made after market hours yesterday announced the successful closure of inspection with the receipt of establishment inspection report (EIR) from United States Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility situated at Kandivalasa, Andhra Pradesh during the period 13 to 17 January 2020 . This facility predominantly caters regulated markets including USA, it added.
SMS Pharmaceuticals is engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and their intermediates. The firm's principal products/services include pharmaceuticals. The company's product range includes API and intermediates.
Currently, the stock is trading 49.05% below its 52-week high of Rs 68.70 hit on 13 March 2019. It is 1.89% above its 52-week low of Rs 34.35 hit on 11 March 2020.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
